- In April 2024, Vericel Corporation, a leader in advanced cell therapies, announced the expansion of its stem cell manufacturing facility in the U.S. to support the increasing demand for autologous cell-based treatments for orthopedic conditions, including osteonecrosis. This move reflects the company's commitment to scaling up production of regenerative therapies such as MACI, used in joint preservation, and reinforces its focus on tackling early-stage osteonecrosis using biologic solutions
- In March 2024, Medtronic plc entered into a strategic research collaboration with orthopedic centers across Europe to evaluate the effectiveness of minimally invasive core decompression systems for treating early-stage femoral head osteonecrosis. The partnership aims to generate real-world evidence supporting less invasive interventions and broaden treatment access through physician training programs
- In March 2024, Sanofi initiated Phase II clinical trials for its investigational bisphosphonate formulation targeting bone remodeling in patients with glucocorticoid-induced osteonecrosis. The trial is being conducted across major hospitals in the U.S., India, and China, indicating a rising focus on pharmaceutical approaches for halting disease progression at early stages
- In February 2024, Zimmer Biomet launched a new orthopedic implant system specifically designed for hip resurfacing and replacement in patients affected by late-stage osteonecrosis. This next-generation implant offers improved bone preservation and has already received CE Mark approval, with U.S. FDA submission expected by Q4 2025
- In January 2024, Smith+Nephew announced the successful commercialization of its Bone Graft Substitute (BGS) platform in Asia-Pacific markets, particularly targeting orthopedic surgeons treating osteonecrosis of the femoral head. The platform combines synthetic scaffolds and bone morphogenetic proteins (BMPs) to stimulate natural bone healing and reduce the need for total joint replacement
